{"disease":{"id":"prom","name":"prom"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"dextromethorphan-hydrobromide","indication_name":"Productive Cough Promotion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROMETHORPHAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Expectorant [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Herpes Simplex in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Varicella-Zoster in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"arsenic-trioxide","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trisenox","generic_name":"ARSENIC TRIOXIDE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"daunorubicine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cytarabine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"6-mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-Mercaptopurine","generic_name":"6-mercaptopurine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"trisenox","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trisenox","company_name":"German AML Cooperative Group","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Purixan","generic_name":"MERCAPTOPURINE","company_name":"Stason Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"mercaptopurine","quality_score":62,"revenue":null,"mechanism":"Purixan works by inhibiting the enzyme responsible for producing prostaglandins, which are involved in inflammation and immune response."},{"drug_id":"multivitamins","indication_name":"Promote Bone and Dental Health","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"multivitamins","company_name":"Faculdade de Medicina do ABC","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200976","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"foscarnet","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"idarubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"vistide","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vistide","company_name":"Gustave Roussy, Cancer Campus, Grand Paris","drug_phase":"marketed","molecular_target":"DNA polymerase catalytic subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xaluprine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xaluprine","company_name":"Kjeld Schmiegelow","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cidofovir","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vistide","generic_name":"CIDOFOVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"cidofovir","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"prevnar-20","indication_name":"Immunocompromised adults (CLL, HIV, autoimmune)","indication_type":"pipeline","phase":"phase_3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"}],"offLabel":[],"totalMarketed":50,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT00904579","title":"Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease","phase":"","overall_status":"COMPLETED","enrollment_count":19929901,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05020145","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1277747,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04323137","title":"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML","phase":"NA","overall_status":"COMPLETED","enrollment_count":117649,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT03565562","title":"Preventing Psychological Distress and Suicidal Behaviours: a Web-based and Mobile Suicide Prevention Intervention in the General Population","phase":"NA","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04839848","title":"Chronic Postoperative Pain After the Lichtenstein Groin Hernioplasty","phase":"","overall_status":"COMPLETED","enrollment_count":80733,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05012163","title":"Lottery Incentive Nudges to Increase Influenza Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":57581,"lead_sponsor_name":"National Bureau of Economic Research, Inc.","has_results":true},{"nct_id":"NCT05009251","title":"Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":45061,"lead_sponsor_name":"National Bureau of Economic Research, Inc.","has_results":true},{"nct_id":"NCT05509270","title":"Efficacy of Communication Modalities for Promoting Flu Shots","phase":"NA","overall_status":"COMPLETED","enrollment_count":43225,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT04526873","title":"Encouraging Annual Wellness Visits Among ACO Beneficiaries","phase":"NA","overall_status":"COMPLETED","enrollment_count":41472,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT05509283","title":"Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications","phase":"NA","overall_status":"COMPLETED","enrollment_count":40671,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT02907125","title":"Extended Evaluation of School-based Health Promotion Programmes in Bihar, India","phase":"NA","overall_status":"COMPLETED","enrollment_count":29527,"lead_sponsor_name":"Sangath","has_results":false},{"nct_id":"NCT06653374","title":"Perinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT05000619","title":"Encouraging Overdue Healthcare Appointment Scheduling Among Patients With Chronic Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":21562,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT04289623","title":"Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication","phase":"","overall_status":"COMPLETED","enrollment_count":13546,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT05224297","title":"Patient Experience Data in Radiation Oncology","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03965754","title":"Assessing the Impact of myHealth Rewards Enrollment Emails","phase":"","overall_status":"COMPLETED","enrollment_count":5697,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT04461470","title":"6-Month Outcomes of PEMF to Nucleotide Sources Revealing Cell Sensory Experience in Pain Relief, Stress Relief and Anti Ageing Restoration","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"hz Clinic","has_results":false},{"nct_id":"NCT05439044","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)","phase":"","overall_status":"COMPLETED","enrollment_count":4235,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06523712","title":"A Scalable, Teacher-delivered, School-based Oral Health Intervention for Pakistani Lower Secondary Schoolchildren","phase":"NA","overall_status":"COMPLETED","enrollment_count":4055,"lead_sponsor_name":"Universiti Putra Malaysia","has_results":false},{"nct_id":"NCT01365026","title":"PVS: Innovative Programs For Healthy Lifestyle Promotion in Primary Care: 'Prescribe Healthy Life'","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4017,"lead_sponsor_name":"Basque Health Service","has_results":false},{"nct_id":"NCT03136211","title":"Complex Multiple Risk Behavior Intervention in People Between 45 to 75 Years (EIRA Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3062,"lead_sponsor_name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","has_results":false},{"nct_id":"NCT05782036","title":"Development, Validation and Clinical Application of a Recovery Scale After Cardiac Surgery: the Fuwai-CRS (Fuwai- Cardiac Recovery Scale)","phase":"","overall_status":"COMPLETED","enrollment_count":3043,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06174844","title":"Assessment of the Humanisation of Care in Hospitals in Andalusia-Spain","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of Seville","has_results":false},{"nct_id":"NCT03423615","title":"Lay Fieldworker Led School Health Program for Rural Primary Schools","phase":"NA","overall_status":"COMPLETED","enrollment_count":2909,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04045288","title":"SWITCH Implementation Effectiveness Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1984,"lead_sponsor_name":"Iowa State University","has_results":false},{"nct_id":"NCT07172074","title":"Comparing Relative Strengths of Statistical Associations Between Psychological Traits and Vaccination-Related Outcomes I","phase":"NA","overall_status":"COMPLETED","enrollment_count":1786,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT06377397","title":"Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Indian Council of Medical Research","has_results":false},{"nct_id":"NCT04735744","title":"Evaluation of Allied Healthcare in Patients Recovering From COVID-19","phase":"","overall_status":"UNKNOWN","enrollment_count":1441,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06495554","title":"Danish Vulva Cancer Recurrence Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":1295,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06332248","title":"Possible Effects of the Dietary Supplement Magnesium Compared to Placebo","phase":"NA","overall_status":"COMPLETED","enrollment_count":1013,"lead_sponsor_name":"Dan Hasson","has_results":false},{"nct_id":"NCT06181162","title":"YoPA - A Youth-centred Participatory Action","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT06597318","title":"Trends of Patient-reported Outcome Measures (PROMs) in Multimorbid Medical Patients Hospitalized for an Acute Illness","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Lausanne Hospitals","has_results":false},{"nct_id":"NCT03797898","title":"Well-Child Care Clinical Practice Redesign: A Parent Coach-Led Model of Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":937,"lead_sponsor_name":"Seattle Children's Hospital","has_results":true},{"nct_id":"NCT03646955","title":"Partial Breast Versus no Irradiation for Women With Early Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":926,"lead_sponsor_name":"Danish Breast Cancer Cooperative Group","has_results":false},{"nct_id":"NCT05229016","title":"Priming and Patient Reported Outcome Measures","phase":"NA","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03194854","title":"Well-Being and Physical Activity Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04047342","title":"Assessing the Impact of myHealth Rewards New Hire Enrollment Emails","phase":"","overall_status":"COMPLETED","enrollment_count":824,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT07397013","title":"Adjustment Technique for Occlusal Stabilizing Splint","phase":"NA","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT04043793","title":"ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT05093452","title":"MOTIVAC-MATER-Confiance","phase":"NA","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"Observatoire Regional de la Sante Provence-Alpes-Côte d'Azur","has_results":false},{"nct_id":"NCT05395364","title":"A Health Promotion Intervention for Vulnerable School","phase":"NA","overall_status":"COMPLETED","enrollment_count":735,"lead_sponsor_name":"University of Minho","has_results":false},{"nct_id":"NCT07236034","title":"ARISe at UMass Chan","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT02984007","title":"PROMOtion of VAccination in Canada (PromovaC Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"Université de Sherbrooke","has_results":false},{"nct_id":"NCT06599658","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT04805125","title":"Immunocompromised Swiss Cohorts Based Trial Platform","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT06964633","title":"The Ku Ola Project: Enhancing Health Promotion Among Native Hawaiian Men.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Hawaii","has_results":false},{"nct_id":"NCT06996847","title":"A Protocol to Promote Critical Consumption (PCC)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Universidad de San Martín de Porres","has_results":false},{"nct_id":"NCT05403060","title":"Educational Nutritional Intervention for Adolescents","phase":"NA","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Centro Universitario de Ciencias de la Salud, Mexico","has_results":false},{"nct_id":"NCT04994535","title":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"AbbVie","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}